Table 53Summary evidence profile for pharmacological studies for the prophylaxis of bipolar disorder

DivalproexAntimanic medication
Study IDsWISNER2004ACOHEN1995
Overall quality of evidenceLowLow
Recurrence – all episodesRR = 0.92 (0.44, 1.91)
22% versus 24% (K = 3; n = 78)
RMpproph 03.01
RR = 0.12 (0.02, 0.81)
7% versus 62% (K = 1; n = 27)
RMpproph 04.01
Recurrence – hypomania/maniaRR = 0.73 (0.05, 10.49)
7% versus 9% (K = 1; n = 26)
RMpproph 03.01
N/A
Recurrence – mixed statesRR = 0.37 (0.04, 3.55)
7% versus 18% (K = 1; n = 26)
RMpproph 03.01
N/A
Recurrence – depressionRR = 1.17 (0.53, 2.62)
53% versus 45% (K = 1; n = 26)
RMpproph 03.01
N/A

Notes: RR = relative risk (95% CI); K = number of trials contributing to the summary statistic; n = number of participants; N/A = not available; ‘RMpproph nn.nn’ refers to the relevant forest plot in Appendix 20

From: 7, THE PHARMACOLOGICAL TREATMENT OF MENTAL DISORDERS IN PREGNANT AND BREASTFEEDING WOMEN

Cover of Antenatal and Postnatal Mental Health
Antenatal and Postnatal Mental Health: The NICE Guideline on Clinical Management and Service Guidance.
NICE Clinical Guidelines, No. 45.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2007.
Copyright © 2007, The British Psychological Society & The Royal College of Psychiatrists.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.